Oramed Pharmaceuticals Delays Quarterly SEC Filing

Oramed Pharm ( (ORMP) ) has released a notification of late filing.

Oramed Pharmaceuticals Inc. has filed a Form 12b-25, notifying investors of a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The company, based in New York, says it needs more time to finalize the financial statements for this period.

The primary reason for the delay is logistical: Oramed states that completing and finalizing the required quarterly financial statements would have required unreasonable effort and expense by the original deadline. There is no mention of auditor changes, investigations, or internal control failures as contributing factors.

Crucially for investors, Oramed does not expect any significant change in its results of operations compared with the same quarter of the prior year. In the notification, the company indicates that earnings statements in the delayed Form 10-Q (Quarter Report) should be broadly in line with last year’s corresponding period, though all such expectations remain subject to final review and are effectively forward-looking in nature.

The company has committed to filing the Form 10-Q (Quarter Report) within the standard grace period allowed under SEC rules. Specifically, Oramed anticipates submitting the quarterly report no later than the fifth calendar day after the original due date, which should limit uncertainty and keep the delay relatively short.

Oramed also confirms that all other required periodic reports over the past 12 months have been filed on time, suggesting this is an isolated timing issue rather than a pattern of compliance problems. The notification is signed by President and Chief Executive Officer Nadav Kidron on May 15, 2026, underscoring management’s formal commitment to complete the filing and maintain SEC reporting compliance.

Spark’s Take on ORMP Stock

According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.

The score is held back primarily by weak operating performance and persistent negative operating/free cash flow despite a strong, low-debt balance sheet. Technicals are a meaningful positive with a strong trend and supportive momentum, while valuation looks optically cheap on P/E but is tempered by questions around earnings quality. Recent corporate events add a moderate positive due to monetization/financing and improved optionality in strategic holdings.

To see Spark’s full report on ORMP stock, click here.

More about Oramed Pharm

Average Trading Volume: 147,514

Technical Sentiment Signal: Buy

Current Market Cap: $191.3M

For an in-depth examination of ORMP stock, go to TipRanks’ Overview page.